Navigation Links
Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration
Date:9/23/2008

OSLO, September 23 /PRNewswire/ -- Affitech AS, the Norwegian human antibody therapeutics company, today announced that it has accomplished the second milestone in its research and licensing collaboration with Roche to produce fully human recombinant antibodies against an unnamed oncology target. Affitech has successfully used its MBAS (Molecule Based Antibody Screening) system that included its proprietary antibody library and high throughput screening technology to identify several fully human lead antibody candidates. These were then subjected to further engineering in order to generate final candidates that met Roche's various predetermined success criteria. This accomplishment triggered a milestone payment of an undisclosed amount from Roche to Affitech.

"This was a particularly challenging target that Roche asked us to investigate and we are delighted to have delivered a selected group of antibodies, on schedule, that meet their exacting criteria," commented Martin Welschof, Ph.D., Chief Executive Officer of Affitech.

Affitech and Roche entered into this collaboration in 2007 for Affitech to identify and engineer fully human recombinant antibodies against one of Roche's oncology targets. Under the terms of the agreement Roche will now utilize these antibodies for further preclinical evaluation with exclusive rights to develop and commercialize resulting antibodies. Affitech would receive additional milestone payments upon successful development by Roche of these antibodies in oncology or other indications and royalties on worldwide net sales of any successfully developed product candidates.

Notes to Editors:

About Affitech

Affitech AS is a privately held human therapeutic antibody discovery and development company with headquarters and R&D facilities in Oslo, Norway and its US subsidiary in the San Francisco Bay Area. The Company's current disease focus is oncology and it utilizes two discrete but unique approaches for the discovery of fully human antibodies - (i) Molecule Based Antibody Discovery, and (ii) Cell Based Antibody Discovery. Molecule Based Antibody Discovery involves proprietary PhagemidScreeN and AffiScreeN(TM) technologies and uses validated targets for discovery purpose. Cell Based Antibody Discovery is based on CBAS(TM) technology, which is a "reverse-screening" approach for discovering antibodies and their cognate targets utilizing disease-specific cells. Several of the Company's proprietary product candidates currently in development were generated by CBAS(TM). Affitech also sells its proprietary Protein L product line for the purification of antibody and antibody fragments. Affitech offers collaborators a flexible business model and competitive price structure with low royalty stacking. The Company has concluded deals with commercial organizations such as Omeros, Roche, Peregrine, XOMA, NatImmune, Viventia, Dyax, Micromet, Pharmexa and others. Further information at http://www.affitech.com.

Contacts for Affitech:

Affitech (Norway):

Dr. Martin Welschof

Chief Executive Officer

+47-22-95-87-58

m.welschof@affitech.com

Affitech (USA):

Dr. Rathin C. Das President

+1-925-935-9803

r.das@affitech.com


'/>"/>
SOURCE Affitech AS
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Affitech Appoints Dr. Keith McCullagh as Chairman
2. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
3. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
4. Emisphere Announces Recruitment Phase III Study for Oral Osteoarthritis Treatment
5. China-Biotics, Inc. Announces Results of 2008 Annual General Meeting of Shareholders
6. BioElectronics Corp. Announces $400,000 in New Orders From the Middle East
7. The Michigan Life Sciences Pipeline Announces New Best Practices Seminars Tailored to Michigan Businesses
8. Enigma Diagnostics Announces an Award of GBP 1.8 Million From UK Government
9. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
10. Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
11. Dendreon Announces Webcast Presentation at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
(Date:6/23/2016)... NEW YORK , June, 23, 2016  The ... students to envision new ways to harness living systems ... of Modern Art (MoMA) in New York ... more than 130 participating students, showcased projects at MoMA,s ... included Paola Antonelli , MoMA,s senior curator of ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016   ... management and verification solutions, has partnered with ... software solutions for Visitor Management, Self-Service Kiosks ... provides products that add functional enhancements to ... provides corporations and venues with an automated ...
(Date:6/20/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring announced that ... has secured the final acceptance by all three ... Access Systems (MAS) installed. Furthermore, Securus will have ... installed by October, 2016. MAS distinguishes between legitimate ...
(Date:6/9/2016)... -- Perkotek an innovation leader in attendance control systems is proud to announce the introduction ... to make sure the right employees are actually signing in, and to even control ... ... ... ...
Breaking Biology News(10 mins):